Novel agents in the treatment of atherosclerosis

Robin Fears, Keith Suckling, George Poste

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A recent Biochemical Society Colloquium 'Novel Approaches to the Treatment of Atherosclerosis' discussed some of the potential alternatives to the current lipid-lowering strategies used to influence coronary heart disease morbidity and mortality. Advances in understanding of the conventional low density lipoprotein cholesterol-lowering agents, particulary the fibrates and the statins, from recent experimental and clinical studies, suggest new directions in lipoprotein research. Increased insight into other important determinants of atherosclerosis also indicates the likely requirement for a variety of therapeutic approaches to address plaque stabilisation and rupture. The contributions of oxidised LDL variants and Lipoprotein(a) as risk factors in atherogenesis are assuming increasing importance. Other research has emphasised the many roles of macrophage colony stimulating factor and the opportunities for intervention on smooth muscle cell proliferation. In addition to the difficulties inherent in comparing the virtues of the different categories of novel anti-atherosclerosis agent, other research challenges include development of appropriate animal models and the optimisation of less invasive methods for the measurement of coronary atherosclerosis progression and regression. Other clinical and regulatory issues relate to the choice of surrogate endpoints and the value of shorter studies in high-risk patient populations and of pharmacoeconomic research. While drug development in this area may remain relatively arduous, there are some exciting opportunities in prospect. Because the selection of patients to receive hypocholesterolaemic therapy continues to attract controversy, there is great interest in the direct approaches to influencing atherosclerosis and, hence, addressing the presently unmet medical needs. 1994

Original languageEnglish (US)
Pages (from-to)481-491
Number of pages11
JournalExpert Opinion on Investigational Drugs
Volume3
Issue number5
DOIs
StatePublished - May 1 1994
Externally publishedYes

Fingerprint

Atherosclerosis
Research
Fibric Acids
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmaceutical Economics
Lipoprotein(a)
Macrophage Colony-Stimulating Factor
LDL Cholesterol
Patient Selection
Lipoproteins
Smooth Muscle Myocytes
Coronary Disease
Coronary Artery Disease
Rupture
Animal Models
Biomarkers
Cell Proliferation
Morbidity
Lipids

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Novel agents in the treatment of atherosclerosis. / Fears, Robin; Suckling, Keith; Poste, George.

In: Expert Opinion on Investigational Drugs, Vol. 3, No. 5, 01.05.1994, p. 481-491.

Research output: Contribution to journalArticle

Fears, Robin ; Suckling, Keith ; Poste, George. / Novel agents in the treatment of atherosclerosis. In: Expert Opinion on Investigational Drugs. 1994 ; Vol. 3, No. 5. pp. 481-491.
@article{781874ed4eab4b98a11ad851bf6585b9,
title = "Novel agents in the treatment of atherosclerosis",
abstract = "A recent Biochemical Society Colloquium 'Novel Approaches to the Treatment of Atherosclerosis' discussed some of the potential alternatives to the current lipid-lowering strategies used to influence coronary heart disease morbidity and mortality. Advances in understanding of the conventional low density lipoprotein cholesterol-lowering agents, particulary the fibrates and the statins, from recent experimental and clinical studies, suggest new directions in lipoprotein research. Increased insight into other important determinants of atherosclerosis also indicates the likely requirement for a variety of therapeutic approaches to address plaque stabilisation and rupture. The contributions of oxidised LDL variants and Lipoprotein(a) as risk factors in atherogenesis are assuming increasing importance. Other research has emphasised the many roles of macrophage colony stimulating factor and the opportunities for intervention on smooth muscle cell proliferation. In addition to the difficulties inherent in comparing the virtues of the different categories of novel anti-atherosclerosis agent, other research challenges include development of appropriate animal models and the optimisation of less invasive methods for the measurement of coronary atherosclerosis progression and regression. Other clinical and regulatory issues relate to the choice of surrogate endpoints and the value of shorter studies in high-risk patient populations and of pharmacoeconomic research. While drug development in this area may remain relatively arduous, there are some exciting opportunities in prospect. Because the selection of patients to receive hypocholesterolaemic therapy continues to attract controversy, there is great interest in the direct approaches to influencing atherosclerosis and, hence, addressing the presently unmet medical needs. 1994",
author = "Robin Fears and Keith Suckling and George Poste",
year = "1994",
month = "5",
day = "1",
doi = "10.1517/13543784.3.5.481",
language = "English (US)",
volume = "3",
pages = "481--491",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Novel agents in the treatment of atherosclerosis

AU - Fears, Robin

AU - Suckling, Keith

AU - Poste, George

PY - 1994/5/1

Y1 - 1994/5/1

N2 - A recent Biochemical Society Colloquium 'Novel Approaches to the Treatment of Atherosclerosis' discussed some of the potential alternatives to the current lipid-lowering strategies used to influence coronary heart disease morbidity and mortality. Advances in understanding of the conventional low density lipoprotein cholesterol-lowering agents, particulary the fibrates and the statins, from recent experimental and clinical studies, suggest new directions in lipoprotein research. Increased insight into other important determinants of atherosclerosis also indicates the likely requirement for a variety of therapeutic approaches to address plaque stabilisation and rupture. The contributions of oxidised LDL variants and Lipoprotein(a) as risk factors in atherogenesis are assuming increasing importance. Other research has emphasised the many roles of macrophage colony stimulating factor and the opportunities for intervention on smooth muscle cell proliferation. In addition to the difficulties inherent in comparing the virtues of the different categories of novel anti-atherosclerosis agent, other research challenges include development of appropriate animal models and the optimisation of less invasive methods for the measurement of coronary atherosclerosis progression and regression. Other clinical and regulatory issues relate to the choice of surrogate endpoints and the value of shorter studies in high-risk patient populations and of pharmacoeconomic research. While drug development in this area may remain relatively arduous, there are some exciting opportunities in prospect. Because the selection of patients to receive hypocholesterolaemic therapy continues to attract controversy, there is great interest in the direct approaches to influencing atherosclerosis and, hence, addressing the presently unmet medical needs. 1994

AB - A recent Biochemical Society Colloquium 'Novel Approaches to the Treatment of Atherosclerosis' discussed some of the potential alternatives to the current lipid-lowering strategies used to influence coronary heart disease morbidity and mortality. Advances in understanding of the conventional low density lipoprotein cholesterol-lowering agents, particulary the fibrates and the statins, from recent experimental and clinical studies, suggest new directions in lipoprotein research. Increased insight into other important determinants of atherosclerosis also indicates the likely requirement for a variety of therapeutic approaches to address plaque stabilisation and rupture. The contributions of oxidised LDL variants and Lipoprotein(a) as risk factors in atherogenesis are assuming increasing importance. Other research has emphasised the many roles of macrophage colony stimulating factor and the opportunities for intervention on smooth muscle cell proliferation. In addition to the difficulties inherent in comparing the virtues of the different categories of novel anti-atherosclerosis agent, other research challenges include development of appropriate animal models and the optimisation of less invasive methods for the measurement of coronary atherosclerosis progression and regression. Other clinical and regulatory issues relate to the choice of surrogate endpoints and the value of shorter studies in high-risk patient populations and of pharmacoeconomic research. While drug development in this area may remain relatively arduous, there are some exciting opportunities in prospect. Because the selection of patients to receive hypocholesterolaemic therapy continues to attract controversy, there is great interest in the direct approaches to influencing atherosclerosis and, hence, addressing the presently unmet medical needs. 1994

UR - http://www.scopus.com/inward/record.url?scp=0028307242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028307242&partnerID=8YFLogxK

U2 - 10.1517/13543784.3.5.481

DO - 10.1517/13543784.3.5.481

M3 - Article

AN - SCOPUS:0028307242

VL - 3

SP - 481

EP - 491

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 5

ER -